COMMUNIQUÉS West-GlobeNewswire

Claris Biotherapeutics to Host Virtual KOL Event on Positive CSB-001 Data and the Unmet Need in Limbal Stem Cell Deficiency (LSCD)
15/10/2026
SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where limited or no [...]
Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026
15/10/2026
Dr. Megha Prasad to deliver podium presentation featuring Conavi’s hybrid IVUS–OCT imaging Abstract presentation on saline-based hybrid IVUS–OCT imaging Participation in two CRF Imaging Lab physician education sessions [...]
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
15/10/2026
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on [...]
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
15/10/2026
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding Phase 2 TOIVA Pediatric Analyses Highlight [...]
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
15/10/2026
TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including [...]
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
15/10/2026
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for [...]
SweetWater Brewing Gives Fans the Chance to Win Tickets to Their Dream Show at AEG Venues Across Georgia
15/10/2026
Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West ATLANTA, Oct. 15, 2026 (GLOBE [...]
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
15/10/2026
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube SER-428 significantly reduced gastrointestinal [...]
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
15/10/2026
FDA accepted the resubmission as complete and classified it as a Class 2 response Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027 Ex-U.S. strategy remains on track with Canadian NDS [...]
Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company
15/10/2026
Cronos acquires CanAdelaar for a base purchase price of €57.5 million plus cash earnout of 0.5x Normalized EBITDA 1 in 2026 and 2027 Establishes Cronos’ European platform with #1 market share 2 in the largest adult-use [...]
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
15/10/2026
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield No Thromboembolic Events Were Reported for ADMA IVIG Products Manufactured [...]
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
15/10/2026
BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an [...]
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
15/10/2026
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and [...]
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
15/10/2026
Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of [...]
Affidea signs agreement to acquire two Alliance Medical centres in central London, accelerating its UK growth
15/10/2026
LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Affidea , a leading pan-European provider of community-based clinics, advanced diagnostics and specialist private healthcare services has signed an agreement to acquire two [...]
Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines
15/10/2026
Phase 2b study provides first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes OVX836 did not meet its pre-specified primary endpoint of 50% [...]
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
15/10/2026
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment- [...]
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026
October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to [...]
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026
MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control Phase 1b ‘MTX325-101’ study – taking place [...]

Pages